Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors

被引：0
|
作者：
Wang, J. [1 ]
Johnson, M. [2 ]
Barve, M. [3 ]
Pelster, M. [2 ]
Chen, X. [4 ]
Li, Z. [4 ]
Gordon, J. [4 ]
Reiss, M. [4 ]
Pai, S. [4 ]
Falchook, G. [5 ]
Tolcher, A. [6 ]
机构：
[1] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Tennessee Oncol Drug Dev Unit, Nashville, TN USA
[3] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[4] Erasca Inc, San Diego, CA USA
[5] Sarah Cannon Res Inst HealthONE, Drug Dev Unit, Denver, CO USA
[6] NEXT Oncol, Oncol, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [1] Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
    Anastasios Stathis
    Anthony W. Tolcher
    Judy S. Wang
    Daniel J. Renouf
    Lin-Chi Chen
    Leah H. Suttner
    Tomoko Freshwater
    Andrea L. Webber
    Tapan Nayak
    Lillian L. Siu
    Investigational New Drugs, 2023, 41 : 380 - 390
  • [2] Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
    Stathis, Anastasios
    Tolcher, Anthony W.
    Wang, Judy S.
    Renouf, Daniel J.
    Chen, Lin-Chi
    Suttner, Leah H.
    Freshwater, Tomoko
    Webber, Andrea L.
    Nayak, Tapan
    Siu, Lillian L.
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 380 - 390
  • [3] Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
    Thein, Kyaw Z.
    Fu, Siqing
    Janku, Filip
    Tsimberidou, Apostolia M.
    Piha-Paul, Sarina A.
    Karp, Daniel D.
    Shah, Jatin
    Milton, Denai R.
    Gong, Jing
    Sulovic, Selma
    McQuinn, Lacey
    Stephen, Bettzy A.
    Colen, Rivka R.
    Carter, Brett W.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (01) : 10 - 12
  • [4] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors
    Rivera, Ismael Rodriguez
    Shen, Lin
    Kummar, Shivaani
    Barve, Minal
    Germa, Caroline
    Qi, Chuan
    Chen, Lei
    Milata, Jenny
    Yao, Jenny
    Shen, Li
    Zhu, Xuelian
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Results of study PX-171-007 a phase 1b/2 study of carfilzomib, a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors
    Gordon, M.
    Infante, J.
    Papadopoulos, K. P.
    Lee, P.
    Sausville, E.
    Mendelson, D.
    Wong, A. F.
    Vallone, M.
    Rosen, P. J.
    Burris, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 123
  • [6] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
    Dasari, Arvind
    Kauh, John S.
    Tucci, Christopher
    Nanda, Shivani
    Kania, Marek K.
    Carlisle, Jennifer W.
    Paulson, Andrew Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
    Wang, Xicheng
    Zhou, Jianfeng
    Li, Yan
    Ge, Yuping
    Zhou, Yanping
    Bai, Chunmei
    Shen, Lin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 21 - 33
  • [8] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [9] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [10] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
12345